Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Merck reports positive data from malignant pleural mesothelioma trial

May 25, 2023 By Law Offices of Thomas J. Lamb, P.A.

Merck and the Canadian Cancer Trials Group (CCTG) have reported positive data from the Phase II/III CCTG IND.227/KEYNOTE-483 trial of Keytruda, along with chemotherapy, as first-line treatment for advanced malignant pleural mesothelioma patients.

The open-label, randomised Phase II/III trial has been designed for assessing the combination of Keytruda and chemotherapy to treat unresected advanced malignant pleural mesothelioma patients.

According to the final study analysis, the combination of Keytruda and chemotherapy met the trial’s primary endpoint of overall survival (OS), demonstrating a clinically meaningful and statistically significant improvement in OS compared to chemotherapy alone.

In the trial, the safety profile of Keytruda along with chemotherapy was found to be consistent with previously reported trials.

Merck Research Laboratories senior vice-president, chief medical officer and global clinical development head Dr Eliav Barr said: “Malignant pleural mesothelioma is a rapidly progressing cancer that develops in the lining of the lungs and has a poor prognosis.

“Patients are in need of new treatments that can improve survival outcomes, and these positive results support the potential of Keytruda in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma.”

The IND.227/KEYNOTE-483 trial was sponsored and conducted by CCTG, along with Intergroupe Francophone de Cancérologie Thoracique (IFCT) and the National Cancer Institute of Naples (NCIN).

Merck provided Keytruda as well as support for the trial.

Last month, the company reported that the combination of its Keytruda (pembrolizumab) and chemotherapy (carboplatin and paclitaxel) met the Phase III NRG-GY018 trial’s primary endpoint of progression-free survival (PFS).

[View article at original source]

 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.